Antibody Affinity Maturation Service
Service Overview
JWE focuses on developing high-quality therapeutic antibodies for clients. Leveraging our proprietary Yeast Surface Display (YSD) platform and phage display technologies, combined with advanced computational design and library construction methods, we provide efficient and precise antibody affinity maturation strategies to help optimize parental antibody sequences and rapidly obtain high-affinity antibody candidates.
Service Introduction
In therapeutic antibody development, particularly after humanization of non-human antibodies, improving the binding affinity between the antibody and its target is often required. In vitro antibody affinity maturation can enhance affinity through minimal mutations while achieving maximal performance gains. With more than a decade of technical expertise, JWE has established a complete system including:
- FR and CDR hotspot mutation design: Identify key amino acid residues via computation and structural modeling
- High-quality mutation library construction: Construct mutation libraries using Trimer Codon or semiconductor chip-based synthesis to ensure uniformity and high coverage
- Efficient screening workflow: Utilize yeast or phage display combined with FACS to rapidly obtain high-affinity antibody candidates
Platform Technical Strategies
- Yeast Surface Display (YSD): Suitable for antibody mutation library screening with sizes <107, enabling rapid enrichment of high-affinity variants
- Phage Display: Suitable for large-scale mutation libraries >107
- Trimer Codon / Semiconductor-synthesized Libraries: Avoid NNK/NNM biases and improve library coverage and uniformity
- Computational design with MOE system: Assist in mutation site determination, improving screening efficiency and accuracy
Service Workflow & Timeline
| Step | Service Content | Deliverables | Timeline |
|---|---|---|---|
| Step 1 | 3D antibody modeling to identify FR/CDR hotspot mutation residues |
- Optimized antibody sequences (1–3 variants, at least 5× affinity improvement) - 1 mg corresponding recombinant antibody - Complete analysis report (PDF) |
14–18 weeks |
| Step 2 | FR/CDR combinatorial mutation library synthesis and display platform screening | High-affinity antibody populations | - |
| Step 3 | Antibody production and validation | Recombinant antibodies and affinity validation data | - |
Platform Advantages
- Fully customized display systems: Choose YSD or phage display based on library size and parental sequence characteristics
- Mature and efficient affinity optimization platform: Combine computational design with high-throughput screening
- 3D visualization modeling: Highlight hotspot mutation sites with intuitive visualization
- High-coverage, highly uniform libraries: Ensure diversity and screening success rate
- One-stop service: From sequence design to antibody validation with a complete technological workflow
